Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin (bevacizumab) in adult patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results